Symbiotec Pharmalab targets CDMO and complex injectables-led growth and margin expansion

Investment View and Valuation

In its October 1, 2026 initiation report, ICICI Securities views Symbiotec Pharmalab Limited as a company transitioning from a legacy active pharmaceutical ingredients (API) business to higher-value complex injectables and contract development and manufacturing organisation (CDMO) businesses. The broker has initiated coverage with a BUY rating and values the company at 19 times FY29E EBITDA of Rs 542.4 crore.

The report indicates a target price of Rs 1,540 against a CMP of Rs 1,200, implying 28 per cent upside.

Core API Business and Market Position

Symbiotec is a Madhya Pradesh-based API company with global leadership in corticosteroid and steroidal-hormone APIs. It has approximately 38.2 per cent global volume share in corticosteroids and 23.8 per cent in steroidal hormones.

Its portfolio comprises around 60 sterile and non-sterile products and serves over 200 customers across more than 40 countries, including over 150 export customers. Average relationships with the top 10 customers are nearly 10 years.

ICICI Securities expects the core corticosteroid and steroidal-hormone API business to grow at around 8 to 10 per cent CAGR from FY26 to FY29E. Growth is expected to be supported by stable base demand and new products such as Vegan D3, docosahexaenoic acid, UDCA and Premarin.

CDMO and Complex Injectables Growth Strategy

The principal growth thesis is the ramp-up of recent investments in CDMO and complex injectables. Symbiotec has invested over Rs 1,000 crore in these new businesses, including Rs 376 crore in complex injectables and Rs 584 crore in CDMO.

The company has commissioned 400 KL of fermentation capacity at Ujjain for CDMO and has several global and Indian contracts, largely incorporating take-or-pay terms. These contracts cover insulin drug substance, classical fermentation APIs, alternate proteins and nutraceutical or industrial biotechnology applications.

ICICI Securities expects CDMO revenue to gain traction from Europe-based alternate-protein contracts in FY27E, followed by insulin and US alternate-protein contracts in FY28E, reaching about Rs 360 crore by FY29E.

Complex Injectables Opportunity

Complex injectables are centred on double-chamber vials, bags and syringes. Symbiotec is developing methylprednisolone sodium succinate and hydrocortisone sodium succinate double-chamber vial products, and has partnered with global specialty pharmaceutical companies for commercialisation of one product.

Milestone income is expected in FY27E, while commercial revenue is expected from FY28E. The broker notes that double-chamber injectable combinations can command a 20 to 50 per cent price premium over conventional injectables due to better stability, dosing accuracy, ease of use and lower contamination and wastage risk.

Financial Outlook

Reported FY26 revenue was Rs 869.1 crore, EBITDA was Rs 237.9 crore and EBITDA margin was 27.4 per cent. ICICI Securities forecasts revenue, EBITDA and EBITDA margin as follows:

Revenue is projected to grow at a FY26 to FY29E CAGR of 23.3 per cent. EBITDA margin is expected to expand to 33.3 per cent by FY29E as CDMO and double-chamber vial contributions increase. Quarterly margins may remain volatile because of the timing of milestone payments and technology-transfer income.

Returns, Management Ambition and Key Risks

Return ratios have been depressed by capex undertaken ahead of revenue generation. Of cumulative gross capex of over Rs 1,475 crore as of June 30, 2026, only around 40 per cent was revenue generating.

The broker expects utilisation and profitability to lift return ratios, with RoCE estimated at 17.8 per cent and RoIC at 18.6 per cent by FY29E. Management aspires to grow revenue three times and EBITDA four times over five years from the FY26 base.

Key risks include:

• Delays in commercialisation or customer offtake from new verticals.
• Regulatory or quality-control failures at facilities serving regulated markets.
• Customer concentration. The top five customers accounted for 43.0 per cent of FY26 revenue, while the top 10 accounted for 57.6 per cent.